

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/72, 47/26, 38/00	A1	(11) International Publication Number: WO 96/19207
		(43) International Publication Date: 27 June 1996 (27.06.96)

(21) International Application Number: PCT/SE95/01541
(22) International Filing Date: 19 December 1995 (19.12.95)
(30) Priority Data:
9404468-2 22 December 1994 (22.12.94) SE

(71) Applicant (for all designated States except US): ASTRA
AKTIEBOLAG [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BÄCKSTRÖM, Kjell
[SE/SE]; Notariegränden 4, S-226 47 Lund (SE). JOHANS-
SON, Ann [SE/SE]; Arkeologvägen 65, S-226 54 Lund (SE).
LINDEN, Helena [SE/SE]; Dag Hammarskjölds väg 5 B, S-
224 64 Lund (SE).

(74) Agent: ASTRA AKTIEBOLAG; Patent Dept., S-151 85
Södertälje (SE).

(81) Designated States: AL, AM, AT, AU, BB, BG, BR, BY, CA,
CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP,
KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG,
MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European
patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE,
LS, MW, SD, SZ, UG).

Published

With international search report.

(54) Title: POWDER FORMULATIONS CONTAINING MELEZITOSE AS A DILUENT

(57) Abstract

A powder formulation for the administration of medically useful polypeptides, comprising a medically useful polypeptide with melezitose as diluent.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LJ	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

Powder formulations containing melezitose as a diluent

Field of the invention

The present invention relates to powder formulations containing medically useful
5 polypeptides.

Technical background

Polypeptide powders containing medically useful polypeptides and pharmaceutically
acceptable carriers or diluents may be prepared for administration by inhalation or
10 otherwise. Inhalable polypeptide powder preparations have been described in
WO95/00127 and WO95/00128.

Diluents are commonplace in pharmaceutical preparations, especially in formulations for
inhalation. They are used to stabilise various drugs during manufacture and storage and to
15 adjust the amount of powder making up unit doses - in general, powder inhalers are
capable of delivering a drug substance with good dose accuracy only for certain dose sizes,
while different drugs have different potencies and must therefore be delivered in different
amounts. As these amounts are often too small for proper dose accuracy to be ensured,
diluents are added to give the desired dose size.

20

Previously, reducing sugars such as lactose and glucose have been used as diluents in
polypeptide powder formulations. These however have a tendency to react with
polypeptides and are therefore unsatisfactory.

25 It is suggested in WO95/00127 and WO95/00128, relating to polypeptide powders for
inhalation, that non-reducing sugars such as raffinose, melezitose, lactitol, maltitol,
trehalose, sucrose, mannitol and starch may be preferred additives for the polypeptide
powders.

It has now been found that melezitose is an exceptionally good diluent compared with other possible non-reducing sugar diluents for polypeptide powder formulations, giving an unexpectedly high respirable fraction of powder when inhaled.

5 Summary of the invention

Accordingly, the present invention provides a powder formulation for the administration of medically useful polypeptides, comprising a medically useful polypeptide with melezitose as diluent.

10

Administration is preferably by inhalation.

The melezitose may comprise for example D-melezitose (α -D-melezitose), β -D-glucopyranoside, O- α -D-glucopyranosyl-1,3- β -D-fructofuranosyl (β -D-melezitose) or
15 isomelezitose. The melezitose may be for example in the form of the monohydrate or dihydrate.

The powder formulation of the present invention has been found to be very effective upon oral inhalation, giving a superior fraction of respirable particles compared with powder
20 formulations with other diluents, as is described herein. As a result, a higher fraction of the inhaled powder will reach the lungs and a higher fraction of the polypeptide is utilised.

The powder formulation of the present invention is also suitable for use in nasal inhalation.

25 The powder formulation of the present invention is suitable for both systemic and local treatment. When local action is desired in the respiratory tract, no other ingredient is necessary in the powder formulation. When systemic action is required, an enhancer, i.e. a substance which enhances the absorption of the polypeptide in the respiratory tract, should generally be included in the formulation. Such substances are included in WO95/00127
30 and WO95/00128, incorporated herein by reference. In certain cases, small polypeptides are absorbed in the respiratory tract without the aid of an enhancer. In these cases an

enhancer may be excluded from the formulations of melezitose and the medically useful polypeptide. In different embodiments therefore the present invention provides a powder comprising a medically useful polypeptide and melezitose; a powder comprising a medically useful polypeptide and melezitose and specifically including an enhancer; and a powder comprising a medically useful polypeptide and melezitose, specifically excluding an enhancer. The powder according to the present invention excluding an enhancer, is most useful (a) when local action of the polypeptide is desired; or (b) when systemic action of smaller polypeptides which are absorbed in the respiratory tract without the aid of an enhancer is desired. Polypeptides which are absorbed in the respiratory tract without the aid of an enhancer may be identified using conventional cell or, preferably, animal models, in the latter case by comparing plasma polypeptide levels following administration, for example by means of a Wright Dust Feed apparatus, of powders with and without enhancer. The powder specifically including an enhancer according to the present invention, is most useful when systemic action of polypeptides which are not absorbed in the respiratory tract without the aid of an enhancer, is desired.

Preferred enhancers include C₈₋₁₆ fatty acids and salts thereof, bile salts, phospholipids and alkyl saccharides.

Of the fatty acids and salts thereof, C₈-C₁₆ fatty acids salts are preferred. Examples of preferred fatty acid salts are sodium, potassium and lysine salts of caprylate (C₈), caprate (C₁₀), laurate (C₁₂) and myristate (C₁₄). As the nature of the counterion is not of special significance, any of the salts of the fatty acids are potentially useful. A particularly preferred fatty acid salt is sodium caprate.

Suitable bile salts may be for example salts of cholic acid, chenodeoxycholic acid, glycocholic acid, taurocholic acid, glycochenodeoxycholic acid, taurochenodeoxycholic acid, deoxycholic acid, glycodeoxycholic acid, taurodeoxycholic acid, lithocholic acid, and ursodeoxycholic acid.

Of the bile salts, trihydroxy bile salts are preferred. More preferred are the salts of cholic, glycocholic and taurocholic acids, especially the sodium and potassium salts thereof. The most preferred bile salt is sodium taurocholate.

- 5 Suitable phospholipids may be for example single-chain phospholipids, for example lysophosphatidylcholines, lysophosphatidylglycerols, lysophosphatidylethanolamines, lysophosphatidylinositols and lysophosphatidylserines or double-chain phospholipids, for example diacylphosphatidylcholines, diacylphosphatidylglycerols, diacylphosphatidylethanolamines, diacylphosphatidylinositols and
10 diacylphosphatidylserines.

Of the phospholipids, diacylphosphatidylglycerols and diacylphosphatidylcholines are preferred, for example dioctanoylphosphatidylglycerol and dioctanoylphosphatidylcholine.

- 15 Suitable alkyl saccharides may be for example alkyl glucosides or alkyl maltosides, such as decyl glucoside and dodecyl maltoside.

The most preferred enhancers are bile salts.

- 20 The polypeptide may be any medically or diagnostically useful peptide or protein of small to medium size, i.e. up to about 40 kD molecular weight (MW). It is expected that polypeptides having a molecular weight of up to 30 kD will be most useful in the present invention, such as polypeptides having a molecular weight of up to 25 kD or up to 20 kD, and especially up to 15 kD, up to 10kD, or up to 5 kD.

25

- The polypeptide is preferably a peptide hormone such as insulin, glucagon, C-peptide of insulin, vasopressin, desmopressin, corticotropin (ACTH), corticotropin releasing hormone (CRH), gonadotropin releasing hormone (GnRH), gonadotropin releasing hormone agonists and antagonists, gonadotrophin (luteinizing hormone, or LHRH),
30 calcitonin, parathyroid hormone (PTH), bioactive fragments of PTH such as PTH(34) and PTH(38), growth hormone (GH) (for example human growth hormone (hGH)), growth

hormone releasing hormone (GHRH), somatostatin, oxytocin, atrial natriuretic factor (ANF), thyrotropin releasing hormone (TRH), deoxyribonuclease (DNase), prolactin, and follicle stimulating hormone (FSH), and analogues of any of the above.

- 5 Other possible polypeptides include growth factors, interleukins, polypeptide vaccines, enzymes, endorphins, glycoproteins, lipoproteins, and polypeptides involved in the blood coagulation cascade.

The preferred polypeptide is insulin.

10

In the powder formulation of the present invention melezitose may be present in an amount of up to almost 100% by weight of the total powder. For example the melezitose may be present in an amount between 20% and almost 100%, for example between 30% and almost 100% or between 40% and almost 100%, or between 50% and almost 100%, e.g.
15 between 60% and almost 100%, or between 65% and almost 100%, such as between 65% and 99% or between around 70% and around 99% such as between 80% and 98% by weight of the total weight of powder.

As with all pharmaceutical preparations, certain additives, for example for pH regulation,
20 for example organic or inorganic salts, to give taste, or to increase stability, for example preservatives, carbohydrates, amino acids, peptides and proteins, may also be included in the formulation.

When the powder preparation of the present invention is intended for oral inhalation the
25 polypeptide should consist of (a) primary particles having a diameter of less than about 10 microns, for example between 0.01 and 10 microns and preferably between 0.1 and 6 microns, for example between 0.01 and 5 microns, or (b) agglomerates of said particles. Preferably at least 50% of the polypeptide consists of particles within the desired size range. For example at least 60%, preferably at least 70%, more preferably at least 80% and
30 most preferably at least 90% of the polypeptide consists of particles within the desired size range, when oral inhalation is desired.

The melezitose in the formulation for oral inhalation may largely consist of particles having a diameter of less than about 10 microns so that the resultant powder as a whole consists of optionally agglomerated primary particles having a diameter of less than about 10 microns; alternatively the melezitose may largely consist of much bigger particles ("coarse particles"), so that an "ordered mixture" may be formed between the active compounds and the melezitose. In the ordered mixture, alternatively known as an interactive or adhesive mixture, the polypeptide particles will be fairly evenly distributed over the surface of the coarse melezitose. Preferably in such case the active compounds are not in the form of agglomerates prior to formation of the ordered mixture. The coarse particles may have a diameter of over 20 microns, such as over 60 microns. Above these lower limits, the diameter of the coarse particles is not of critical importance so various coarse particle sizes may be used, if desired according to the practical requirements of the particular formulation. There is no requirement for the coarse particles in the ordered mixture to be of the same size, but the coarse particles may advantageously be of similar size within the ordered mixture. Preferably, the coarse particles have a diameter of 60 - 800 microns.

The particle size is less important in nasal inhalation although small particles are desirable. An ordered mixture would not normally be employed in nasal inhalation.

A useful mechanism for delivery of the powder into the respiratory tract of a patient is through a portable inhaler device suitable for dry powder inhalation. Many such devices, typically designed to deliver antiasthmatic or antiinflammatory agents into the respiratory system, are on the market.

The described powder preparation can be manufactured in several ways, using conventional techniques. Particles in a required size range may be obtained by any known method, for example by freeze-drying or by controlled crystallisation methods, for example crystallisation using supercritical fluids; or by micronisation methods. For example, one can dry mix the polypeptide and melezitose (and optional enhancer) powders, and then micronise the substances together; alternatively, the substances can be micronised separately, and then

mixed. Where the compounds to be mixed have different physical properties such as hardness and brittleness, resistance to micronisation varies and they may require different pressures to be broken down to suitable particle sizes. When micronised together, therefore, the obtained particle size of one of the components may be unsatisfactory. In such case it
5 would be advantageous to micronise the different components separately and then mix them.

It is also possible, where an ordered mixture is not intended, first to dissolve the components in a suitable solvent, e.g. water, to obtain mixing on the molecular level. This procedure also makes it possible to adjust the pH-value to a desired level. To obtain a powder, the solvent
10 must be removed by a process which retains the polypeptide's biological activity. Suitable drying methods include vacuum concentration, open drying, spray drying, and freeze drying. Temperatures over 40°C for more than a few minutes should generally be avoided, as some degradation of the polypeptide may occur. Following the drying step, the solid material can, if necessary, be ground to obtain a coarse powder, then, if necessary, micronised.

15 If desired, the powder can be processed to improve the flow properties, e.g., by dry granulation to form spherical agglomerates with superior handling characteristics, before it is incorporated into the intended inhaler device. In such a case, the device would be configured to ensure that the agglomerates are substantially deagglomerated prior to exiting the device,
20 so that the particles entering the respiratory tract of the patient are largely within the desired size range.

Where an ordered mixture is desired, the active compound may be processed, for example by micronisation, in order to obtain, if desired, particles within a particular size range. The
25 melezitose may also be processed, for example to obtain a desired size and desirable surface properties, such as a particular surface to weight ratio, or a certain ruggedness, and to ensure optimal adhesion forces in the ordered mixture. Such physical requirements of an ordered mixture are well known, as are the various means of obtaining an ordered mixture which fulfills the said requirements, and may be determined easily by the skilled person according to
30 the particular circumstances.

The powders of the present invention are useful for the local or systemic treatment of diseases and may be administered for example via the upper and lower respiratory tract, including by the nasal route. As such the present invention also provides said powder for use in therapy; the use of the powder in the manufacture of a medicament for the treatment of diseases via the respiratory tract; and a method for the treatment of a patient in need of therapy,
5 comprising administering to said patient a therapeutically effective amount of the powder of the present invention.

The diseases which may be treated with the powder of the present invention are any of those which may be treated with the particular polypeptide in each case; for example
10 powders containing insulin according to the present invention may be used for example in the treatment of diabetes; powders containing corticotropin may be used for example in the treatment of inflammatory diseases; powders containing GnRH may be useful for example in the treatment of male infertility. The indications for all of the mentioned polypeptides are well known. The powders of the present invention may also be used in prophylactic
15 treatment.

Although the powders of the present invention are particularly directed to polypeptide powders for inhalation from dry powder inhaler devices, the polypeptide powders may also
20 be included in compositions for other forms of administration, for example in injection solutions and aerosol formulations.

The respirable fraction upon oral inhalation of the powders of the present invention may be determined by the method described in the Examples herein.

25

Certain embodiments of the invention are illustrated in the following Examples, which are not to be considered limiting:

Example 1

30

Insulin (0.6g) was dissolved in distilled water (50 ml). Diluent (14.4g) was added and dissolved and the pH was adjusted to 7.4. The obtained solid cake was crushed, sieved, and

micronised in a jet mill. The micronised powders were agglomerated and filled into a Turbuhaler® dry powder inhaler and the dose was released at an air flow rate of 60 L/min, under varying conditions.

- 5 The released dose was collected using a multi-stage impinger; the content of insulin in each stage of the impinger was determined using liquid chromatography with detection at 235 nm. The results were as follows.

fraction of particles of size less than 6.8 μm , %	30%RH, 60 L/min	75%RH, 60 L/min	30%RH, 60 L/min, open moisture provocation**
Diluent			
myo-inositol	52	18	3
maltitol	66	10	8
mannitol	65	17	9
trehalose	58	22	17
raffinose	40	17	
palatinite	30	18	15
stachyose	52	5	
melezitose	73	39	32

- 10 ** the preparation had been moisture provoked for three days in open plates.

It is clearly seen that melezitose gave the highest fraction of respirable particles in all cases. Moreover the respirable fraction is not as dependent on external factors when melezitose is the diluent.

Example 2

Insulin (12 parts) was dissolved in distilled water. Sodium taurocholate (enhancer, 4 parts) was added. Various diluents (84 parts) were added and dissolved and the pH was adjusted to 7.4. The solution was concentrated by evaporation of the water. The obtained solid
5 cake was crushed, sieved, and micronised in a jet mill.. The micronised powder was agglomerated and filled into a Turbuhaler ® dry powder inhaler and the dose was released at an air flow rate of 60 L/min, under varying conditions.

The released dose was collected using a multi-stage impinger; the content of insulin in each
10 stage of the impinger was determined using liquid chromatography with detection at 235 nm. The results were as follows.

Fraction of particles of size less than 6.8 µm, %	30% RH 60 L/min	90% RH 60 L/min
melezitose	65.0	21.7
trehalose	60.5	6.3
myo-inositol	71.6	10.9
mannitol	79.4	4.4
maltitol	44.7	0.1

These results show that the formulation with melezitose is much less affected by high
15 humidity in the air.

Example 3

Micronised formulations containing DNase, surfactant (sodium taurocholate or
20 dioctanoylphosphatidylglycerol), and melezitose (ratio DNase : surfactant : melezitose 1 : 0.33 : 98.67, total weight 50 mg), were added to propellant 134a or propellant 227 (approximately 10 ml) in a plastic coated glass bottle. The formulations were mixed with an ultra turrax for approximately 10 minutes.

Identical formulations were prepared to which 5% of ethanol prior to the mixing with an ultraturrax apparatus for approximately 10 minutes.

- 5 The quality of the suspensions formed were assessed immediately and after 20 hours. In all cases good suspensions were observed.

This shows that the melezitose-containing formulations of the present invention are suitable for use in formulations other than for dry-powder inhalation, in this case in aerosol
10 formulations.

Claims

1. A powder formulation for the administration of medically useful polypeptides, comprising a medically useful polypeptide with melezitose as diluent.
- 5 2. A powder formulation as claimed in claim 1, wherein the melezitose comprises D-melezitose (α -D-melezitose), β -D-glucopyranoside, O- α -D-glucopyranosyl-1,3- β -D-fructofuranosyl (β -D-melezitose) or isomelezitose.
- 10 3. A powder formulation as claimed in claim 1 or claim 2, wherein the melezitose is in the form of the monohydrate or dihydrate.
4. A powder formulation as claimed in any of claims 1-3, wherein the formulation includes an enhancer which enhances the absorption of the medically useful polypeptide in
15 the lower respiratory tract.
5. A powder formulation as claimed in claim 4, wherein the enhancer is selected from C₈
16 fatty acids and salts thereof, bile salts, phospholipids and alkyl saccharides.
- 20 6. A powder formulation as claimed in claim 4, wherein the enhancer is selected from the sodium, potassium and lysine salts of caprylate (C₈), caprate (C₁₀), laurate (C₁₂) and myristate (C₁₄).
7. A powder formulation as claimed in claim 4, wherein the enhancer is selected from
25 bile salts selected from salts of cholic acid, chenodeoxycholic acid, glycocholic acid, taurocholic acid, glycochenodeoxycholic acid, taurochenodeoxycholic acid, deoxycholic acid, glycodeoxycholic acid, taurodeoxycholic acid, lithocholic acid, and ursodeoxycholic acid.
- 30 8. A powder formulation as claimed in claim 4, wherein the enhancer is selected from trihydroxy bile salts.

9. A powder formulation as claimed in claim 4, wherein the enhancer is selected from the salts of cholic, glycocholic and taurocholic acids.
- 5 10. A powder formulation as claimed in claim 4, wherein the enhancer is selected from the sodium and potassium salts of cholic, glycocholic and taurocholic acids.
11. A powder formulation as claimed in claim 4, wherein the enhancer is sodium taurocholate.
- 10 12. A powder formulation as claimed in claim 4, wherein the enhancer is selected from single-chain phospholipids.
13. A powder formulation as claimed in claim 4, wherein the enhancer is selected from
15 lysophosphatidylcholines, lysophosphatidylglycerols, lysophosphatidylethanolamines, lysophosphatidylinositols and lysophosphatidylserines.
14. A powder formulation as claimed in claim 4, wherein the enhancer is selected from double-chain phospholipids.
- 20 15. A powder formulation as claimed in claim 4, wherein the enhancer is selected from diacylphosphatidylcholines, diacylphosphatidylglycerols, diacylphosphatidylethanolamines, diacylphosphatidylinositols and diacylphosphatidylserines.
- 25 16. A powder formulation as claimed in claim 4, wherein the enhancer is selected from dioctanoylphosphatidylglycerol and dioctanoylphosphatidylcholine.
17. A powder formulation as claimed in claim 4, wherein the enhancer is selected from alkyl glucosides or alkyl maltosides, such as decyl glucoside and dodecyl maltoside.
- 30

18. A powder formulation as claimed in any of claims 1-17, wherein the polypeptide is selected from insulin, glucagon, C-peptide of insulin, vasopressin, desmopressin, corticotropin (ACTH), corticotropin releasing hormone (CRH), gonadotropin releasing hormone (GnRH), gonadotropin releasing hormone agonists and antagonists,
5 gonadotrophin (luteinizing hormone, or LHRH), calcitonin, parathyroid hormone (PTH), bioactive fragments of PTH such as PTH(34) and PTH(38), growth hormone (GH) (for example human growth hormone (hGH)), growth hormone releasing hormone (GHRH), somatostatin, oxytocin, atrial natriuretic factor (ANF), thyrotropin releasing hormone (TRH), deoxyribonuclease (DNase), prolactin, and follicle stimulating hormone (FSH), and
10 analogues thereof.

19. A powder formulation as claimed in any of claims 1-18, wherein the polypeptide is of molecular weight (MW) up to about 40 kD.

15 20. A powder formulation as claimed in claim 19, wherein the polypeptide has a molecular weight of up to 30 kD.

21. A powder formulation as claimed in claim 19, wherein the polypeptide has a molecular weight of up to 25kD.

20

22. A powder formulation as claimed in claim 19, wherein the polypeptide has a molecular weight of up to 20 kD.

23. A powder formulation as claimed in claim 19, wherein the polypeptide has a molecular
25 weight of up to 15 kD.

24. A powder formulation as claimed in claim 19, wherein the polypeptide has a molecular weight of up to 10 kD.

30 25. A powder formulation as claimed in claim 19, wherein the polypeptide has a molecular weight of up to 5 kD.

26. A powder formulation as claimed in claim 18, wherein the polypeptide is insulin.
27. A powder formulation as claimed in any preceding claim, wherein the melezitose is
5 present in an amount of between 20% and almost 100% by weight of the powder.
28. A powder formulation as claimed in any claim 27, wherein the melezitose is present in
an amount of between 30% and almost 100% by weight of the powder.
- 10 29. A powder formulation as claimed in claim 28, wherein the melezitose is present in an
amount of between 40% and almost 100% by weight of the powder.
30. A powder formulation as claimed in claim 29, wherein the melezitose is present in an
amount of between 50% and almost 100% by weight of the powder.
15
31. A powder formulation as claimed in claim 30, wherein the melezitose is present in an
amount of between 60% and almost 100% by weight of the powder.
32. A powder formulation as claimed in claim 31, wherein the melezitose is present in an
20 amount of between 65% and almost 100% by weight of the powder.
33. A powder formulation as claimed in claim 32, wherein the melezitose is present in an
amount of between 65% and 99% by weight of the powder.
- 25 34. A powder formulation as claimed in claim 33, wherein the melezitose is present in an
amount of between 70% and 99% by weight of the powder.
35. A powder formulation as claimed in claim 34, wherein the melezitose is present in an
amount of between 80% and 98% by weight of the powder.

36. A powder formulation as claimed in any preceding claim, wherein the polypeptide comprises (a) primary particles having a diameter of between 0.01 and 10 microns, or (b) agglomerates of said particles.
- 5 37. A powder formulation as claimed in any preceding claim, wherein the polypeptide comprises (a) primary particles having a diameter of between 1 and 6 microns, or (b) agglomerates of said particles.
38. A powder formulation as claimed in claim 35 or 36, wherein at least 50% of the
10 polypeptide consists of particles within the desired size range.
39. A powder formulation as claimed in claim 38, wherein at least 60% of the polypeptide consists of particles within the desired size range.
- 15 40. A powder formulation as claimed in claim 39, wherein at least 70% of the polypeptide consists of particles within the desired size range.
41. A powder formulation as claimed in claim 40, wherein at least 80% of the polypeptide consists of particles within the desired size range.
- 20 42. A powder formulation as claimed in claim 41, wherein at least 90% of the polypeptide consists of particles within the desired size range.
43. A powder fomulation as claimed in any preceding claim, wherein the melezitose consists
25 of particles having a diameter of less than about 10 microns.
44. A powder formulation as claimed in any of claims 1-43, wherein the melezitose consists of coarse particles of diameter over 20 microns.
- 30 45. A powder formulation as claimed in claim 44, wherein the melezitose consists of coarse particles having a diameter of 60 - 800 microns.

46. A powder formulation as claimed in any of claims 1 - 45 , wherein an enhancer is excluded from the formulation.

5 47. A method for the manufacture of a powder formulation as claimed in any of claims 1-43 and 46, comprising the steps of: dry mixing of the polypeptide and melezitose, and optional enhancer powders; and micronising the substances together.

10 48. A method for the manufacture of a powder formulation as claimed in any of claims 1-43 and 46, comprising the steps of: micronising the polypeptide and micronising and melezitose, and optional enhancer powders separately; and mixing the micronised powders.

15 49. A method for the manufacture of a powder formulation as claimed in any of claims 1-43 and 46 comprising the steps of: dissolving the components in a solvent; optionally adjusting the pH-value to a desired level; removing the solvent; drying; and optional micronising of the obtained solid.

50. A method for the manufacture of a powder formulation as claimed in claim 44 or 45, comprising dry mixing melezitose and micronised polypeptide powders.

20

51. A powder as claimed in any of claims 1-50, for use in therapy.

52. The use of a powder as claimed in any of claims 1-50 in the manufacture of a medicament for the treatment of diseases via the respiratory tract.

25

53. A method for the treatment of a patient in need of therapy, comprising administering to said patient a therapeutically effective amount of a powder as claimed in any of claims 1-50.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 95/01541

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: A61K 9/72, A61K 47/26, A61K 38/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EMBASE, USFULLTEXT, WPI, WPIL, CLAIMS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9118091 A1 (QUADRANT HOLDINGS CAMBRIDGE LIMITED), 28 November 1991 (28.11.91), page 6, line 9 - page 7, line 11, the claims --	1-52
A	EP 0364235 A1 (TOYO JOZO KABUSHIKI KAISHA), 18 April 1990 (18.04.90) --	1-52
A	WO 8705213 A1 (CHIESI FARMACEUTICI S.P.A.), 11 Sept 1987 (11.09.87) -- -----	1-52

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

& document member of the same patent family

Date of the actual completion of the international search

27 March 1996

Date of mailing of the international search report

02 -04- 1996

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Anneli Jönsson

Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 95/01541

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 56
because they relate to subject matter not required to be searched by this Authority, namely:
See PCT Rule 39.1(iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

05/02/96

International application No.

PCT/SE 95/01541

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A1- 9118091	28/11/91	AU-A- 7872591 EP-A- 0541556 JP-T- 5508315	10/12/91 19/05/93 25/11/93
EP-A1- 0364235	18/04/90	JP-A- 2104531	17/04/90
WO-A1- 8705213	11/09/87	AU-B,B- 597964 CA-A- 1297012 DE-D,T- 3787502 EP-A,B- 0239798 EP-A,B- 0258356 SE-T3- 0258356 JP-T- 63502895 ZA-A- 8701523	14/06/90 10/03/92 20/01/94 07/10/87 09/03/88 27/10/88 24/08/87